Skip to main content
Clinical Trials/ISRCTN21643919
ISRCTN21643919
Completed
未知

Effects of a cognitive-behavioural mindfulness intervention upon quality of life, depression and fatigue among multiple sclerosis (MS) patients

niversity Hospital Basel (Switzerland)0 sites150 target enrollmentMay 16, 2008

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple sclerosis
Sponsor
niversity Hospital Basel (Switzerland)
Enrollment
150
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

2010 results in: https://www.ncbi.nlm.nih.gov/pubmed/20876468 (added 11/06/2019)

Registry
who.int
Start Date
May 16, 2008
End Date
June 30, 2009
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity Hospital Basel (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • 1\. Both males and females, aged 18 \- 70 years
  • 2\. Verified diagnosis of MS with an expanded disability status scale score of less than or equal to 6\.0 (from no disability to moderately severe disability MS) and no more than one step increase within the last year. We include patients with the followng types of disease:
  • 2\.1\. Relapsing\-remitting MS and no more than two exacerbations within the last year, with at least three months since start of last relapse; or
  • 2\.2\. Secondary progressive disease
  • 3\. Patients who have not initiated or changed treatment with a disease\-modifying drug within the past three months
  • 4\. Patients who have not been treated with corticosteroids within the previous 30 days
  • 5\. Time since onset of disease will be evaluated and considered in statistical analyses but will not form a criterion for enrolment into the study

Exclusion Criteria

  • 1\. Serious psychological disorders other than depression and anxiety syndromes, such as psychotic disorders, bipolar disorders, borderline personality disorders or active substance abuse disorders
  • 2\. Evidence of dementia as indicated by testing below the fifth percentile in at least three of six dimensions of neuropsychological functioning (i.e. attention and concentration, processing speed, executive function, verbal memory, and verbal processing)
  • 3\. Suicidality
  • 4\. Other life\-threatening or severely disabling physical disorders
  • 5\. Current MS exacerbation
  • 6\. Other disorders of the central nervous system (CNS) besides MS
  • 7\. Symptomatic medication has been altered within the past three months
  • 8\. Pregnancy
  • 9\. Inability to understand written and spoken German

Outcomes

Primary Outcomes

Not specified

Similar Trials